CD133 is one of the most common stem cell markers, and functional single nucleotide polymorphisms (SNPs) of CD133 may modulate its gene functions and thus cancer risk and patient survival. We hypothesized that potentially functional CD133 SNPs are associated with gastric cancer (GC) risk and survival. To test this hypothesis, we conducted a case-control study of 371 GC patients and 313 cancer-free controls frequency-matched by age, sex, and ethnicity. We genotyped four selected, potentially functional CD133 SNPs (rs2240688A>C, rs7686732C>G, rs10022537T>A, and rs3130C>T) and used logistic regression analysis for associations of these SNPs with GC risk and Cox hazards regression analysis for survival. We found that compared with the miRNA binding site rs2240688 AA genotype, AC þ CC genotypes were associated with significantly increased GC risk (adjusted OR ¼ 1.52, 95% CI ¼ 1.09-2.13); for another miRNA binding site rs3130C>T SNP, the TT genotype was associated with significantly reduced GC risk (adjusted OR ¼ 0.68, 95% CI ¼ 0.48-0.97), compared with CC þ CT genotypes. In all patients, the risk rs3130 TT variant genotype was significantly associated with overall survival (OS) (adjusted P trend ¼ 0.016 and 0.007 under additive and recessive models, respectively). These findings suggest that these two CD133 miRNA binding site variants, rs2240688 and rs3130, may be potential biomarkers for genetic susceptibility to GC and possible predictors for survival in GC patients but require further validation by larger studies.
INTRODUCTION
Gastric cancer (GC) is the fourth most common cancer worldwide and the second most frequent cause of all cancer deaths [1] . It is believed that both environmental and genetic factors, such as Helicobacter pylori [2] , alcohol consumption [3] , smoking [4] , and family cancer history [5] , may play roles in the etiology. In addition, patients diagnosed with latestages of GC suffer from increased mortality and morbidity [6] . Hence, it is imperative to identify biomarkers for prevention, early diagnosis, monitor tumor progression and potential therapeutic targets of GC.
Cancer stem cells (CSCs) have been hypothesized as the origin of cancer. Like normal stem cells, CSCs are immortal and can self-renew and differentiate into all types of cells [7] . CD133 (also called AC133 or PROM1) is a trans-membrane cell-surface glycoprotein, a specific surface marker found in embryonic stem cells, normal tissue stem cells, stem cell niches, and circulating endothelial progenitors as well as CSCs [8] .
Single-nucleotide polymorphisms (SNPs) have been believed to harbor information about genetic variation in functionality of the genome and susceptibility to cancer, representing a rich source for investigating functional biomarkers implicated in cancer etiology as well as patient treatment outcomes [9] . For example, a common missense SNP (Met1Thr, rs2294008) in exon 1 of the prostate stem cell antigen (PSCA) gene is not only associated with susceptibility to diffuse-type GC in Japanese [10] , Korean [10] , Chinese [11] and Caucasian [12] populations, but also with survival in Chinese patients with diffuse-type GC [13] .
Although its function still remains unclear, CD133 is broadly found among normal tissue stem cells as well as putative CSC populations, thought to serve as a marker of asymmetric division, lineage plasticity, tumor cell dormancy, and inherent embryonic gene expression [8] . A recent case-control study in a Chinese population [14] , in which 13 potentially functional SNPs were genotyped in the promoter, exon and 3 0 -UTR regions of CD133, showed that rs2240688C variant genotypes were associated with reduced risk of lung cancer and may also be associated with a protective effect on OS. Further, the rs2240688A-to-C transition was found to reduce CD133 expression as measured by a new binding site of microRNA hsa-miR-135a/b in a functional assay. In another study, Pohl et al. genotyped three SNPs (rs2240688, rs3130, and rs2286455) located in the 3 0 -untranslated region of CD133 in 91 patients with metastatic colorectal cancer who had been treated with bevacizumab-based chemotherapy, they found that patients with the favorable combination of alleles (either homozygous for C/C in both polymorphisms or the combination of C/T in rs2086455 with either C/T or T/T in rs3130) showed a significantly increased PFS, compared with a decreased PFS for patients with C/C in one polymorphism and C/T or T/T in the other polymorphism [15] . Therefore, we hypothesized that functional stem cell marker SNPs in CD133 could modulate susceptibility to and prognosis of GC. In the present study, we tested this hypothesis by assessing the associations of functional SNPs in CD133 with both GC risk and survival.
MATERIALS AND METHODS

Study Subjects
Study subjects were patients with newly diagnosed and histologically confirmed GC at The University of Texas MD Anderson Cancer Center (Houston, TX) between March 2002 and February 2012, who were recruited for an ongoing case-control study. Meanwhile, cancer-free control subjects were also recruited by using frequency matching on age, sex, and ethnicity from an ongoing molecular epidemiology study of the head and neck cancer in the nearly same period [16] . These cancer-free control subjects were hospital visitors who were neither seeking health care, nor genetically unrelated to the cases. Additional information about risk factors, such as smoke [current smoker, former smoker (quit >1 year), and never smoked] and alcohol use [current drinker, former drinker (quit >1 year), and never drinker], family history of any cancer in first-degree relatives, was collected from each eligible subject. A written informed consent was obtained, and a one-time blood sample was taken from each of the subjects. The study protocol was approved by The University of Texas MD Anderson Cancer Center institutional review board.
Outcome Data Collection
All cases included patients who had adenocarcinoma located at the gastroesophageal junction (GEJ, entailing tumors arising between 5 cm proximal to the z-line and 5 cm distal to the z-line into the stomach) or at the stomach. The overall survival (OS) time was calculated from the date of registration at M.D. Anderson to the date of last contact or death. Patients who were still alive at the last contact were considered as a censored event in the analysis. The age at diagnosis, sex, and type of treatments (i.e., surgery and chemotherapy) were used as covariates in the analysis. H. pylori infection status was confirmed in serum H. pylori antibody tested by ELISA.
SNP Selection and Genotyping
Genomic DNA was extracted from the buffy coat fraction of each blood sample by using a Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. DNA purity and concentrations were determined by spectrophotometric measurement of absorbance at 260 and 280 nm by UV spectrophotometer.
All common [minor allele frequency (MAF) ! 0.05 in Caucasians] SNPs with potentially functional significance [that is, located in the splicing regulation region, the transcription factor binding site (TFBS), the coding regions with amino acid changes, or the 3 0 -untranslated regions (3 0 -UTRs), according to NCBI dbSNPs and SNPinfo Web Server (http://snpinfo. niehs.nih.gov/snpfunc.htm) (the last search date: May, 2012)] in CD133 were identified ( Supplementary  Fig. S1 ). As a result, four CD133 SNPs (rs2240688A>C, rs7686732C>G, rs10022537T>A, and rs3130 C>T) were selected and genotyped by using the TaqMan methodology in 384-well plates, and the outputs were read with the Sequence Detection Software on an ABIPrism 7900 instrument, according to the manufacturer's instructions, Applied Biosystems (Foster City, CA), which had also supplied primers and probes. Each plate included four negative controls, duplicated positive controls and eight repeated samples. The conditions of amplification were as follows: 508C for 2 min, 958C for 10 min followed by 40 cycles of 958C for 15 s, and 608C for 1 min.
Statistical Analysis
The x 2 tests were performed to compare the distributions of demographic variables and selected risk factors, such as smoking status, alcohol use and family history of cancer, between cases and controls. The Hardy-Weinberg equilibrium was tested by a goodness-of-fit x 2 test to compare the observed genotype frequencies with the expected ones in cancer-free controls. The associations of genotypes of CD133 SNPs with risk of GC were estimated by calculating the odds ratios (OR) and their 95% confidence intervals (CIs) from both univiariate and multivariate logistic regression models, followed by stratification analysis. All these analyses were performed with or without adjustment for demographic variables and selected risk factors. Kaplan-Meier plots and log-rank test were applied to assess differences in OS by genotypes from each SNP. Hazard ratios (HR) and their corresponding 95% CIs for OS were estimated by applying the Cox proportional hazards regression model with adjustment for ethnicity, alcohol, stage, location, and application of surgery, chemotherapy, and radiotherapy. Proc HAPLOTYPE in SAS/Genetics software using the expectationmaximization (EM) algorithm was conducted to generate maximum likelihood estimates of haplotype frequencies based on the observed genotypes. Haplotypes with frequencies <5% were combined into one group. All tests were two-sided, and a P < 0.05 was considered the cut-off for statistical significance. All of the statistical analyses were performed with Statistical Analysis System software (Version 9.2; SAS Institute, Cary, NC).
RESULTS
Demographic Characteristics and Risk Factors for GC
The present study included 371 GC patients and 313 cancer-free controls. Table S1 summarizes the distribution of demographic characteristics and selected risk factors for GC. Due to frequency matching used in the study design, there were neither significant difference in distributions of age (median age of 59 years), sex and ethnicity, nor were there differences in frequency distributions of smoking, drinking, and family cancer history status between cases and controls. However, these variables were further adjusted for in further multivariate logistic regression models to control for any residual confounding on the main effect of selected SNPs.
CD133 Genotypes and Risk of GC
Genotype and allele distributions of the selected four functional CD133 SNPs between the cases and controls are listed in Table 1 . The observed genotype frequencies of these four SNPs were all in agreement with those expected by the Hardy-Weinberg equilibrium in control subjects (P ¼ 0.360 for rs2240688 A>C, P ¼ 0.721 for rs7686732 C>G and P ¼ 0.886 for rs10022537 T>A), except for rs3130 (P ¼ 1.833E-10 for rs3130 C>T). Compared with the rs2240688 A allele, the C allele was associated with significantly increased GC risk in an allele dose-response manner (P trend ¼ 0.037); Furthermore, compared with the AA genotype, the AC þ CC genotypes were associated with significantly increased GC risk under a dominant model (adjusted OR ¼ 1.52, 95% CI ¼ 1.09-2.13). For the CD133 rs3130 C>T SNP, another CD133 SNP in the miRNA binding sites, the TT genotype was associated with significantly reduced GC risk under a recessive model, compared with the CC þ CT genotypes (adjusted OR ¼ 0.68, 95% CI ¼ 0.48-0.97; Table 1 ).
We further performed the stratified analysis for the CD133 SNPs in the miRNA binding site, rs2240688 A>C, by age, sex, ethnicity, smoking status, drinking status, and family history of cancer. Compared with the AA genotype, the elevated risks associated with rs2240688 AC þ CC variant genotypes did remain statistically significant in the subgroup of <59 years, males, current smokers, ever drinker, and with family history (P < 0.05), but a borderline elevated risk in the subgroup of ever smokers (P ¼ 0.051; Table 2 ).
Characteristics of the GC Patients
Clinical and pathological characteristics of the 336 patients who had available follow-up data on outcome are shown in Table S2 . There were 207 males (61.61%) and 129 females (38.39%), whose median age was 59 years. Using the Cox hazards regression analysis for OS by clinicopathological characteristics, we found that age, sex, smoking, family history, and H. pylori infection status were not statistically associated with OS (P ¼ 0.275, 0.168, 0.297, 0.092, 0.906, and 0.507, respectively), but ethnicity and alcohol status were (P ¼ 0.045 and 0.016, respectively).
Of the 260 patients with follow-up data, 188 (77.38%) had tumors located at the stomach and 76 (22.62%) had tumors located at the GEJ. Of these, 182 (54.17%) patients were intestinal 130 (38.69%), signet ring (8.34%), and others 24 (7.14%). We grouped the types of differentiation into the following two categories: poor and moderate-well, and the number and percentage of these two groups were 75 (22.32%) and 255 (75.89%; six cases with data missing), respectively. In all patients, clinicopathological characteristics, including histology and differentiation status, were not significantly associated with OS in the univariate analysis (P ¼ 0.691 and 0.061, respectively), but tumor location was (P < 0.0001). Clinical tumor stages according to the International Union against Cancer (UICC) criteria were as follows: 97 (28.87%) had stage I þ II and 215 (63.99%) had stage III þ IV. Among the 167 patients, 54 (16.07%) received surgery, 205 (61.01%) received chemotherapy, and 65 (19.35%) received radiotherapy; at the end of the follow-up period, 178 (52.98%) patients had died. The median follow-up time was 18.0 months, and the median survival time for all patients was 29.00 AE 3.30 months. Advanced stage, surgery, chemotherapy, and radiotherapy were all associated with OS (P ¼ 0.000, 0.000, 0.002, and 0.005, respectively; Table S2 ). Because ethnicity, alcohol, stage, location, application of surgery, chemotherapy, and radiotherapy may be confounding factors for the effect of the genotypes on OS, these variables were further adjusted for in the multivariable analysis for the main effect of the selected CD133 SNPs.
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The genotype distributions of the four SNPs in CD133 and their associations with OS are summarized in Table 3 . In all patients, variant genotypes of rs2240688 A>C and rs3130 C>T were statistically significantly associated with OS (log-rank P ¼ 0.047 under an additive model for rs2240688, Figure 1A ; log-rank P ¼ 0.033 under a recessive model for rs2240688, Figure 1B ; log-rank P ¼ 0.018 under an additive model for rs3130, Figure 1C ; log-rank P ¼ 0.017 under a recessive model for rs3130, Figure 1D ). After adjustment for ethnicity, alcohol, stage, tumor location, surgery, chemotherapy and radiotherapy, the rs2240688 C variant genotype were not significantly associated with OS, while the rs3130 T variant genotypes remained significantly associated with OS (adjusted P trend ¼ 0.016 under an additive model Figure 1C ; adjusted HR ¼ 0.77, 95% CI ¼ 0.63-0.93, adjusted P ¼ 0.007 under a recessive model Figure 1D ), but this association was not observed for the other two SNPs investigated in this study. We further performed the stratified analysis for rs3130 C>T by age, sex, ethnicity, smoking status, drinking status, family history of cancer, application for surgery, chemotherapy and radiotherapy. Compared with the CC þ CT genotype, the OS associated with the rs3130 TT variant genotype also remained statistically significant in the subgroup of <59 years, male, white, ever smokers, never drinker, without family history, and without surgery, without chemotherapy nor without radiotherapy (P < 0.05; Table 4 ). We found that rs2240688 C variant genotypes were significantly associated with tumor location under all three genetic models, with metastasis and clinical stage under both addictive and recessive models and that rs3130 T variant genotypes were only associated with H. pylori infection under a dominant model (Table 5) .
CD133 Haplotypes and GC Risk and Survival
We also explored the haplotypes in determining their association with GC risk and survival. As shown in Figure S1 , based on genotyping data of 371 cases and 313 controls, these four validated CD133 SNPs are in low LD with the highest found for rs3130 and rs2240688 (r 2 ¼ 0.13). Six haplotypes were shown to have frequencies >5% among all the cases and control, while other less common haplotypes (frequencies <5%) were combined into one group in the analysis. The six common haplotypes in the order of CD133 rs2240688A>C, rs7686732C>G, rs10022537T>G and rs3130T>C
(A-C-T-T, A-C-T-C, C-C-T-C, A-C-A-C, A-C-A-T, and A-G-T-T) accounted
for 88.68% and 92.65% of the chromosomes of the cases and controls, respectively. Of these, A-C-T-T and C-C-T-C were shown to be significantly different between the cases and the controls (adjusted P ¼ 0.010 and 0.001, respectively) and C-C-T-C was associated with increased GC risks (crude OR ¼ 1.67, 95% CI ¼ 1.20-2.31 and adjusted OR ¼ 1.76, 95% CI ¼ 1.25-2.49, respectively), compared with the A-C-T-T haplotype. A-C-T-C was statistically significantly associated with poor OS (crude HR ¼ 1.14, 95% CI ¼ 0.85-1.53 and adjusted HR ¼ 1.46, 95% CI ¼ 1.07-1.99, adjusted P ¼ 0.017, respectively), compared with the A-C-T-T haplotype. Although the combined group of other uncommon haplotypes was also associated with statistically significantly increased GC risk and survival, the results might have been biased due to inadequate sample sizes (Table S3) .
DISCUSSION
In this hospital-based case-control study, we found that the variant rs2240688 C allele in the miRNA binding site of the stem cell marker gene CD133 was associated with significantly increased GC risk in an allele dose-response manner, whereas for rs3130C>T, another SNP in the miRNA binding site of CD133, the TT genotypes were associated with significantly 
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reduced GC risk under a recessive model. In all patients, variant genotypes of rs2240688 and rs3130 were statistically significantly associated with OS; and variant genotypes of rs2240688 were also significantly associated with tumor location, metastasis and clinical stage, whereas rs3130 T variant genotypes were associated only with H. pylori infection. After adjustment for ethnicity, alcohol, stage, tumor location, surgery, chemotherapy and radiotherapy, the rs2240688 C variant genotypes were not significantly associated with OS, while the rs3130 TT genotype remained significantly associated with OS. Additionally in the stratified analysis, the rs2240688A>C variant genotypes also showed some effects in subgroups of smoking, drinking family history status and surgery, chemotherapy and radiotherapy. In further haplotype analysis, the C-C-T-C haplotype was associated with a significantly increased GC risk, and the A-C-T-C haplotype was statistically significantly associated with poor OS, both compared with the A-C-T-T haplotype. However, because these SNPs are potentially functional (Table S4 ) and are not in LD (Table SS) , the haplotype effects may be attributed to single SNP effects.
The CSC theory proposes that cancers are maintained by subpopulations of tumor cells that possess stem cell and progenitor characteristics. These cells can initiate tumor formation, differentiate along multipotent pathways, and they are relatively resistant to conventional chemotherapy [17] and will eventually form metastasis as a "seed" [18] . Recent studies have defined a subset of cancer stem cells found in cancers of the breast [19] , brain [20] , blood [21] , colon [22] , pancreas [23] , lung [24] , liver [25] , skin [26] , ovaries [27] , bladder [28] , head and neck [29] , and stomach [30, 31] .
CD133 (prominin-1) is a 120-kDa glycoprotein with an N-terminal extracellular domain and two large extracellular loops, which are strongly N-glycosylated, and an intracellular C-terminus [32] . In GC, nearly half of human tumor samples are positive for CD133, and the positivity seems to be correlated with tumor progression [33, 34] , but it is controversial whether CD133 is a surface marker that may enrich the putative gastric CSC fraction [35] .
While tobacco use and alcoholic consumption have been regarded as the major risk factors for GC and CSC has been hypothesized as the origin of GC, few studies have investigated the relationship between tobacco use, alcoholic consumption and gastric stem cell. In the present study, SNPs in the miRNA binding sites of the stem cell marker gene CD133, rs2240688 A>C and rs3130 C>T, showed statistically significant associations with GC risk in subgroups of smokers, drinkers and those with a family history of cancer. These data inferred that the miRNA binding site SNPs in the 3 0 UTR of CD133 may be functional by interacting with environmental risk factors and stem cells and thus may contribute to GC susceptibility, which are consistent with stem cell and CSC hypothesis.
Previous study has indicated that expression of the CD133 protein and mRNA is associated with the occurrence of lymph node metastasis, later TNM stage and poorer survival of GC patients [33, 34, 36] . Indeed, in the present study, variant genotypes of rs2240688 and rs3130 in the miRNA binding sites of CD133 were also statistically significantly associated with OS, whereas variant genotypes of rs2240688 were significantly associated with metastasis and clinical stage. Bioinformatics analysis (SNPinfo Web server: http:// snpinfo.niehs.nih.gov/) predicted that the rs2240688 A-to-C transition gained a new binding site of the microRNA hsa-miR-135a/b or has-miR-942, and hsamiR-519e to target CD133 rs3130 C or T allele. Recently, Cheng et al. validated that the rs2240688 A-to-C transition gained a new binding site of the microRNA hsa-miR-135a/b and decreased the CD133 expression by functional assays [14] . Since the sequence complementarity play an essential role in the interaction of miRNA with its targets, it is conceivable that SNPs in a target-binding site could alter the miRNA-mRNA interaction and thus affect the expression of miRNA targets. So, the present study suggests that the metastasis may be an intrinsic property of small cellular populations-CSC and that CD133 might modify metastasis competence of GC by the miRNA binding site polymorphisms, which could be a putative target for improved therapies for treating metastasis.
Previous reports indicated that GEJ may be different from distant GC with poorer prognosis [37, 38] . In the present study, we showed that GEJ had poorer OS than distant GC (MST 17 vs. 34 months), that distributions of the variant genotypes of rs2240688 were significantly different between GEJ and distant GC, and that GC cases with the homozygous CC variant genotype also had a greater risk of GEJ and a poorer survival. Interestingly, as shown in the SNPinfo Web Server (http://snpinfo.niehs.nih.gov/ snpfunc.htm), rs2240688 was the only common functional SNP predicted as having different effects between alleles in the CD133 gene. Given that GEJ may be different from GC because of different cultural or epidemiologic/epigenetic factors involved [39, 40] , our results also suggested that CD133 might 
genetically modify GC risk and prognosis differently in the GEJ and distant GC.
Our data suggested that patients carrying the rs3130TT genotype had a significantly decreased risk of GC, and that GC cases with the TT genotype had significantly better survival; in addition, patients carrying a rs2240688C allele had a significantly increased risk, and GC cases with the homozygous variant CC genotype also had a greater risk of GEJ, metastasis and advanced clinical stage; moreover, two haplotypes were significantly associated with susceptibility to and survival of GC, indicating that these protective/risk effects of the variant alleles did extend to disease severity, a finding consistent with stem cell and CSC hypothesis, suggesting CD133 as a putative GC stem cell marker.
Because the present study is, to our knowledge, the first study on SNPs of the stem cell marker gene and GC risk or prognosis with a limited sample size, particularly for the subgroup analysis, our findings are best considered preliminary. As one of most common surface markers of stem cell and CSC [8] , CD133 SNPs may not be a specific but common marker for susceptibility to and prognosis of cancer. In addition, the current study lacked of information on the H. pylori infection status of the control subjects, although we did find that rs3130 variant genotypes were associated with H. pylori infection in GC patients. Since H. pylori infection in GC patients was relatively uncommon in the US, compared with those in Asian countries [41] , all controls and 66.07% (222/336) patients recruited in our study were not tested for the infection upon their visits to the hospital. Therefore, inclusion of the information about H. pylori infection should be considered in future larger studies to best illustrate the interaction between environmental and genetic factors in the GC etiology and prognosis. Lastly, current studies had made many comparisons, which might have led to possible false positive findings. Therefore, larger studies are warranted to further assess the role of these SNPs in the etiology and prognosis of various kinds of cancer, particularly in different ethnic groups. 
